Amycretin is a novel unimolecular co-agonist that synergistically activates GLP-1 and amylin receptors. Dual agonism engages hindbrain satiety and delays gastric emptying to overcome efficacy ceilings of current monotherapies. Oral amycretin achieves 13.1% weight loss at 12 weeks, surpassing existing oral agents. Subcutaneous administration yields 24.3% weight loss in 36 weeks with rapid onset.

Before age 50, the body has considerable metabolic resilience. After 50, several things shift simultaneously. Visceral fat accumulation increases, even without major weight gain. Arterial stiffness progresses. The kidneys begin to lose some filtering capacity. The heart’s electrical system becomes more vulnerable to rhythm disturbances. And chronic low-grade inflammation — driven partly by excess fat tissue and partly by the aging process itself — begins to accelerate damage across multiple organ systems.Obesity does not cause cardiovascular disease in isolation, but it intensifies nearly every risk factor: high blood pressure, insulin resistance, abnormal cholesterol, systemic inflammation, and sleep apnea all worsen with excess weight. Treating obesity, therefore, is not cosmetic medicine — it is preventive cardiology.

North American hospitality and foodservice operators face rapidly evolving menu demands driven by GLP-1 medication influences, functional beverages, and consumer preference for authentic global cuisine. A comprehensive F&B Trends Guide identifies twelve key trends shaping 2026-2027, offering practical strategies to enhance margins and competitiveness. The most significant shift concerns customers' fundamental relationship with mealtimes themselves, with beverage offerings gaining equal importance to cuisine. Success increasingly depends on deeper ingredient sourcing and culinary craft rather than constant innovation. The guide provides chef-developed recipes and actionable guidance, emphasizing that most trends require strategic thinking about existing menus and supplier relationships rather than substantial capital investment.

This document outlines comprehensive pharmacy management drug policies designed to establish standardized protocols for pharmaceutical operations and controlled substance handling. The policy framework addresses critical aspects including inventory management, dispensing procedures, staff responsibilities, and compliance with regulatory requirements. It serves as an essential reference guide for pharmacy personnel to maintain operational efficiency, ensure patient safety, and uphold legal and ethical standards in drug distribution and administration. The document provides structured guidance on implementing best practices while minimizing risks associated with pharmaceutical management in healthcare settings.

Recent clinical trials demonstrate that GLP-1 receptor agonists offer significant cardiovascular protection beyond weight reduction, particularly for individuals over 50. The SELECT trial, published in November 2023, enrolled over 17,000 non-diabetic adults with existing cardiovascular disease and elevated BMI, revealing that semaglutide substantially reduced major cardiovascular events. After age 50, metabolic changes including increased visceral fat, arterial stiffness, and chronic inflammation amplify cardiovascular risk. GLP-1 medications directly protect the heart, kidneys, and blood vessels through mechanisms independent of weight loss alone, making them valuable preventive cardiology tools for managing obesity and reducing disease progression in older populations at elevated cardiovascular risk.

Limited-time offerings (LTOs) have become a strategic growth driver for the restaurant industry, driven by three primary consumer motivations. Health-conscious diners increasingly seek nutritious menu innovations, while novelty appeals to customers seeking fresh dining experiences and social media engagement opportunities. Value-oriented promotions attract price-sensitive consumers navigating economic pressures. This convergence of health, innovation, and affordability positions LTOs as powerful tools for enhancing customer traffic, generating excitement, and maintaining competitive differentiation. Restaurants leveraging these temporary offerings effectively can drive revenue growth, test new concepts with manageable risk, and respond agilely to evolving consumer preferences in an increasingly competitive market landscape.

GLP-1 receptor agonists, including semaglutide and tirzepatide marketed as Ozempic and Wegovy, have emerged as breakthrough medications extending far beyond their original weight loss applications. Recent research demonstrates therapeutic potential across multiple conditions, including cancer, cardiovascular disease, diabetes, depression, anxiety, endometriosis, and Parkinson's disease. This drug repurposing initiative represents a significant shift in pharmaceutical development, as scientists explore previously unrecognized benefits of these compounds. The findings suggest GLP-1 drugs may address numerous chronic health conditions simultaneously, potentially transforming treatment paradigms across multiple medical specialties and improving patient outcomes significantly.

Portions plus petites, protéines en extra… Les médicaments pour la perte de poids étant de plus en plus répandus, les restaurants américains modifient leur offre pour répondre aux besoins de leurs clients.

SGLT2 inhibitors and GLP-1 receptor agonists have emerged as preferred treatment options for Type II diabetes mellitus, offering significant benefits beyond glycemic control, including cardiovascular protection, renal outcomes improvement, and weight reduction. Primary care practitioners play a vital role in optimizing clinical outcomes by selecting therapies based on individual patient characteristics rather than population-level trial data. SGLT2 inhibitors reduce all-cause and cardiovascular mortality while decreasing heart failure hospitalization risk through mechanisms involving sodium-glucose transport inhibition in the kidney, promoting natriuresis and osmotic diuresis. Individualized treatment approaches considering underlying disease mechanisms, medication efficacy, safety profiles, and patient-specific factors are essential for effective diabetes management.

GLP-1 receptor agonists, including semaglutide and liraglutide, represent a significant advancement in both diabetes management and kidney disease prevention. These medications offer direct renal protection beyond traditional glucose control, slowing chronic kidney disease progression by twenty to thirty percent in clinical trials. GLP-1s work through synthetic incretin hormones that regulate blood sugar while simultaneously protecting kidney cells through direct receptor activation in renal tissue. While most kidney-related side effects remain mild and temporary, primarily affecting hydration through nausea, the benefits substantially outweigh risks for diabetic patients. This dual metabolic and renal approach addresses diabetic nephropathy, which affects nearly forty percent of diabetic individuals, providing a promising new treatment paradigm for kidney health protection.

Recent research demonstrates that glucagon-like peptide-1 receptor agonists significantly reduce cardiovascular and renal risks in type 1 diabetes patients. A large-scale study analyzing data from 174,678 patients found that GLP-1 treatment reduced the 5-year risk of major adverse cardiovascular events by 15% and end-stage kidney disease by 19%, without introducing new safety concerns. These protective effects mirror outcomes observed in type 2 diabetes populations. The findings, derived from electronic health records using propensity score analysis, suggest GLP-1 drugs may offer comparable cardiorenal benefits across diabetes types, potentially expanding treatment options for type 1 diabetes management.

Recent clinical evidence reviews examine muscle loss during GLP-1 receptor agonist therapy for weight management. The landmark STEP-1 trial with semaglutide reported that approximately 38-39 percent of total weight loss comprised lean mass according to dual-energy X-ray absorptiometry (DXA) scans. However, this figure warrants careful interpretation, as DXA scans measure lean soft tissue rather than skeletal muscle exclusively. The category includes water, glycogen, organ tissue, connective tissue, and intramuscular fat, which DXA cannot differentiate. Understanding these measurement limitations is essential for clinicians and patients evaluating the true impact of GLP-1 medications like Ozempic, Wegovy, and Mounjaro on body composition and physical function during weight loss treatment.

Glucotrack’s Continuous Blood Glucose Monitor (CBGM) is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. The Glucotrack CBGM is an Investigational Device and is limited by federal (or United States) law to investigational use.

GLP-1 receptor agonists represent an emerging therapeutic approach in stroke prevention, addressing a critical gap in cardiovascular risk management. This narrative review examines the mechanisms by which GLP-1 agonists may reduce stroke incidence through multiple pathways, including improved glycemic control, weight reduction, and enhanced vascular function. The authors synthesize current evidence regarding the efficacy and safety profile of these agents in high-risk populations. As stroke remains a leading cause of morbidity and mortality globally, identifying novel preventive strategies is essential. This review highlights the promising potential of GLP-1 receptor agonists as adjunctive therapy and discusses implications for clinical practice and future research directions in cerebrovascular disease prevention.

Recent comprehensive analysis of over 90,000 patients across eleven clinical trials reveals that GLP-1 medications reduce the risk of major cardiovascular events by approximately thirteen percent over nearly three years. These drugs, widely recognized for facilitating weight loss, demonstrate substantial cardioprotective benefits extending beyond blood sugar and weight management. The study, published in Cardiovascular Diabetology–Endocrinology Reports, examined long-term outcomes in high-risk populations including individuals with type 2 diabetes, obesity, and existing heart conditions. GLP-1 receptor agonists appear to protect cardiovascular health through multiple mechanisms, including inflammation reduction, improved blood vessel function, and mitigation of key risk factors. This represents the most comprehensive review to date of long-term cardiovascular outcomes associated with these medications when used for prolonged periods exceeding one year.

A University of Virginia-led study presented at Heart Rhythm 2026 reveals that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce atrial fibrillation risk independently of weight loss. The retrospective analysis examined 13,034 patients who initiated GLP-1 RA therapy between 2020 and 2024, compared against a propensity score-matched control group of over 385,000 individuals never receiving the medication. Results demonstrated that GLP-1 RA users experienced significantly better survival rates and substantially lower atrial fibrillation risk, with benefits persisting regardless of weight change. These findings suggest GLP-1 RAs offer direct cardiovascular rhythm benefits beyond their established weight reduction effects, potentially providing important therapeutic advantages for patients at risk of atrial fibrillation.

Recent research demonstrates that GLP-1 receptor agonists, widely prescribed for diabetes and obesity management, provide significant cardiovascular protection in high-risk patient populations. A comprehensive systematic review and meta-analysis examined the long-term safety and efficacy of these medications in individuals with established cardiovascular disease risk factors. The findings reveal that GLP-1 therapies substantially reduce major cardiovascular events, offering promising new therapeutic benefits beyond their original glycemic control applications. While these drugs were initially developed to manage type 2 diabetes, large-scale clinical trials have confirmed their protective effects in vulnerable populations. However, further investigation is needed to understand their potential benefits in broader populations without pre-existing high cardiovascular risk, highlighting opportunities for expanded clinical applications and improved patient outcomes.

This systematic review and meta-analysis synthesizes data from randomized, placebo-controlled cardiovascular outcome trials to evaluate the long-term safety and efficacy of glucagon-like peptide-1 receptor agonists in high-risk cardiovascular populations. GLP-1 receptor agonists are increasingly prescribed for type 2 diabetes and obesity management, yet their sustained cardiovascular effects in vulnerable patients require comprehensive assessment. The study systematically examined trials published between January 2015 and May 2025, focusing on studies with at least 3,000 participants and minimum twelve-month follow-up periods. The primary endpoint assessed was major adverse cardiovascular events, with additional secondary outcomes evaluated. This research provides critical evidence regarding both the metabolic and direct cardiovascular benefits of this important drug class in high-risk populations.

We’ve all heard that making simple lifestyle changes today can help prevent heart disease down the line. But what if you already have key risk factors for heart disease, or even a diagnosis of heart disease itself? Is it too late to turn the tide by turning over a new behavioral leaf?Not according to Fatmata Jalloh, NP-C, a cardiology nurse practitioner with the USC Cardiac and Vascular Institute, part of Keck Medicine of USC. “And don’t take my word for it,” she says. “Studies have proven that lifestyle changes improve your risk factors so you can stop moving along that spectrum to cardiovascular disease.”

GLP-1 receptor agonists — sold under brand names like Ozempic and Mounjaro — were initially developed to treat diabetes. But instead of addressing biomarkers linked to certain disease outcomes, these drugs influence the central cardio-kidney metabolic process, Vaduganathan said. This overarching approach has made GLP-1 drugs the most effective and tolerable choice for most patients treating diabetes and obesity. It’s also what makes it likely that they influence a number of closely related diseases.